SynOx Therapeutics

Addressing the unmet clinical needs of patients with Tenosynovial Giant Cell Tumours (TGCT)

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

In November 2020, SynOx acquired from Roche an exclusive worldwide license to emactuzumab, a potentially best-in-class CSF-1R therapeutic antibody. Emactuzumab has a well-tolerated safety profile and showed remarkable efficacy in patients suffering from diffuse tenosynovial giant cell tumour (TGCT), a rare disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.